Peripheral transluminal angioplasty drug eluting balloons (deb) market pipeline review, 2015

Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) Market - Pipeline Review, 2015: Radiant Insights, Inc Summary GlobalData's Medical Devices sector report, "Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015" provides an overview of Peripheral Transluminal Angioplasty (PTA) Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope - Extensive coverage of the Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry

Reasons to buy The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Identify and understand important and diverse types of Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 Table of Contents Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 6 2 Introduction 7 2.1 Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) Overview 7

3 Products under Development 8 3.1 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 8 3.2 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 9 3.3 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11 3.4 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 13 3.5 PTA Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 14

4 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies 15 4.1 PTA Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 15

4.2 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 16

5 PTA Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview 17 5.1 AnGes MG, Inc. Company Overview 17 5.1.1 AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview 17 5.2 AngioCure, Inc. Company Overview 19 5.2.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19 5.3 AVIDAL Vascular GmbH Company Overview 20 5.3.1 AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview 20 5.4 Bayer HealthCare AG Company Overview 21 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 5.4.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 21 5.5 C. R. Bard, Inc. Company Overview 24 5.5.1 C. R. Bard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24 5.6 Contego Medical, LLC Company Overview 28 5.6.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 28 5.7 eucatech AG Company Overview 29 5.7.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 29 5.8 Eurocor GmbH Company Overview 30 5.8.1 Eurocor GmbH Pipeline Products & Ongoing Clinical Trials Overview 30 5.9 Genesis Technologies, Inc (Inactive) Company Overview 34 5.9.1 Genesis Technologies, Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34 5.10 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview 35 5.10.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 35 5.11 Micell Technologies, Inc. Company Overview 36

5.11.1 Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36 5.12 Minvasys Company Overview 38 5.12.1 Minvasys Pipeline Products & Ongoing Clinical Trials Overview 38 5.13 Neovasc Inc. Company Overview 40 5.13.1 Neovasc Inc. Pipeline Products & Ongoing Clinical Trials Overview 40 5.14 Nipro Corporation Company Overview 42 5.14.1 Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview 42 5.15 QT Vascular Ltd. Company Overview 44 5.15.1 QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 44 5.16 Rontis AG Company Overview 47 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 5.16.1 Rontis AG Pipeline Products & Ongoing Clinical Trials Overview 47 5.17 SiL Vascular Ltd Company Overview 48 5.17.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 48 5.18 SurModics, Inc. Company Overview 49 5.18.1 SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49 5.19 Terumo Corporation Company Overview 51 5.19.1 Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 51 5.20 The Spectranetics Corporation Company Overview 53 5.20.1 The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview 53 5.21 Vascular Nanotransfer Technologies Company Overview 57 5.21.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 57

6 PTA Peripheral Drug Eluting Balloons (DEB)- Recent Developments 59 7 Appendix 77

7.1 Methodology 77 7.2 About GlobalData 79 7.3 Contact Us 80 7.4 Disclaimer 80

List of Tables Table 1: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 8 Table 2: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 10 Table 3: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 12 Table 4: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 13 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 Table 5: PTA Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 14 Table 6: PTA Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 15 Table 7: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 16 Table 8: AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview 17 Table 9: Collategene Drug-Eluting Balloon Catheter - Product Status 17 Table 10: Collategene Drug-Eluting Balloon Catheter - Product Description 18 Table 11: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status 18 Table 12: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description 18 Table 13: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19 Table 14: AngioCure TOP-C Smart Balloon Catheter - Product Status 19 Table 15: AngioCure TOP-C Smart Balloon Catheter - Product Description 19 Table 16: AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview 20 Table 17: WOMBAT - Peripheral Version - Product Status 20

Table 18: WOMBAT - Peripheral Version - Product Description 20 Table 19: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 21 Table 20: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Status 21 Table 21: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Description 22 Table 22: Bayer HealthCare AG - Ongoing Clinical Trials Overview 22 Table 23: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Cotavance Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study 23 Table 24: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - European study of POBA versus Cotavance - Paclitaxel Coated Balloon for Infrapopliteal Lesions in Critical Limb Ischemia 23 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 Table 25: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - IDE Study of POBA versus Cotavance-Paclitaxel Coated Balloon for Infrapopliteal Lesions in Critical Limb Ischemia 23 Table 26: C. R. Bard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24 Table 27: Lutonix 014 DCB Catheter - Product Status 24 Table 28: Lutonix 014 DCB Catheter - Product Description 25 Table 29: C. R. Bard, Inc. - Ongoing Clinical Trials Overview 25 Table 30: Lutonix 014 DCB Catheter - A Prospective, Global Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the LUTONIX Drug Coated PTA Dilatation Catheter 26 Table 31: Lutonix 014 DCB Catheter - A Prospective, Multi-center, Registry of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries (LEVANT 2 Safety Registry) 26 Table 32: Lutonix 014 DCB Catheter - A Prospective, Multi-center, Single Blind, Randomized, Controlled Japanese Population Trial Comparing MD02-LDCB Versus Standard Balloon Angioplasty For Treatment Of Femoropopliteal Arteries 26 Table 33: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries (Lutonix BTK Trial) 27

Table 34: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 28

Table 35: Tibial Artery Drug Eluting Balloon - Product Status 28 Table 36: Tibial Artery Drug Eluting Balloon - Product Description 28 Table 37: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 29 Table 38: Support - Product Status 29 Table 39: Support - Product Description 29 Table 40: Eurocor GmbH Pipeline Products & Ongoing Clinical Trials Overview 30 Table 41: FREEWAY 014 Peripheral Drug Eluting Balloon - Product Status 30 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 Table 42: FREEWAY 014 Peripheral Drug Eluting Balloon - Product Description 31 Table 43: FREEWAY 035 Peripheral Drug-Eluting Balloon - Product Status 31 Table 44: FREEWAY 035 Peripheral Drug-Eluting Balloon - Product Description 32 Table 45: Eurocor GmbH - Ongoing Clinical Trials Overview 32 Table 46: FREEWAY 014 Peripheral Drug Eluting Balloon - Drug Eluting Balloon in Peripheral Intervention for Below-the-knee Arteries with Freeway and Lutonix 33 Table 47: FREEWAY 035 Peripheral Drug-Eluting Balloon - Drug Eluting Balloon in Peripheral Intervention for Below-the-knee Arteries with Freeway and Lutonix 33 Table 48: Genesis Technologies, Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34 Table 49: Genesis DESA Balloon - Product Status 34 Table 50: Genesis DESA Balloon - Product Description 34 Table 51: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 35 Table 52: PTA Drug Eluting Balloon - Product Status 35 Table 53: PTA Drug Eluting Balloon - Product Description 35 Table 54: Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36 Table 55: Drug-Coated Balloon - Product Status 36 Table 56: Drug-Coated Balloon - Product Description 37

Table 57: Minvasys Pipeline Products & Ongoing Clinical Trials Overview 38 Table 58: Danubio PTA Paclitaxel Eluting Over The Wire Balloon Catheter - Product Status 38 Table 59: Danubio PTA Paclitaxel Eluting Over The Wire Balloon Catheter - Product Description 38 Table 60: Danubio PTA Paclitaxel Eluting Rapid eXchange Balloon Catheter - Product Status 39 Table 61: Danubio PTA Paclitaxel Eluting Rapid eXchange Balloon Catheter - Product Description 39 Table 62: Neovasc Inc. Pipeline Products & Ongoing Clinical Trials Overview 40 Table 63: PTA Balloon Catheter - Product Status 40 Table 64: PTA Balloon Catheter - Product Description 41 Table 65: Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview 42 Table 66: Peripheral Drug-Eluting Balloon - Product Status 42 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 Table 67: Peripheral Drug-Eluting Balloon - Product Description 43 Table 68: QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 44 Table 69: Chocolate Touch PTA Drug Coated Balloon - Product Status 44 Table 70: Chocolate Touch PTA Drug Coated Balloon - Product Description 44 Table 71: Silk PTA Balloon Catheter - Product Status 45 Table 72: Silk PTA Balloon Catheter - Product Description 45 Table 73: QT Vascular Ltd. - Ongoing Clinical Trials Overview 45 Table 74: Chocolate Touch PTA Drug Coated Balloon - Clinical Study Evaluating the Chocolate Touch PTCA Coronary Drug-coated Balloon 46 Table 75: Rontis AG Pipeline Products & Ongoing Clinical Trials Overview 47 Table 76: Drug Eluting Dilatation Catheter - Product Status 47 Table 77: Drug Eluting Dilatation Catheter - Product Description 47 Table 78: SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 48 Table 79: Peripheral Vascular Balloon - Product Status 48 Table 80: Peripheral Vascular Balloon - Product Description 48

Table 81: SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49 Table 82: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status 49 Table 83: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description 50 Table 84: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Status 50 Table 85: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Description 50 Table 86: Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 51 Table 87: Drug Coated Balloon Catheter - Product Status 51 Table 88: Drug Coated Balloon Catheter - Product Description 52 Table 89: The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview 53 Table 90: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Status 53 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 Table 91: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Description 54 Table 92: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Status 54 Table 93: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Description 55 Table 94: The Spectranetics Corporation - Ongoing Clinical Trials Overview 55 Table 95: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Global Study Of A Drug-coated Balloon to Treat Obstructive SFA And/Or Popliteal Lesions 56 Table 96: Stellarex Drug Coated Balloon - Superficial Femoral Artery - ILLUMENATE First-in-Human (FIH) Study on the Safety and Effectiveness of Covidien's Advanced Drug-coated Balloon (DCB) Technology 56 Table 97: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Multicenter, Pharmacokinetic Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon 56 Table 98: Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 57 Table 99: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status 57 Table 100: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description 57 Table 101: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status 58

Table 102: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description 58 Table 103: Glossary 78

List of Figures Figure 1: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 8 Figure 2: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 9 Figure 3: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11 Figure 4: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 13 Figure 5: PTA Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 14 Browse Full Report With TOC @ http://www.radiantinsights.com/research/peripheraltransluminal-angioplasty-drug-eluting-balloons-deb-pipeline-review-2015 About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://www.radiantinsightsinc.blogspot.com